AU2004264332B2 - Method and composition for treating burned skin - Google Patents
Method and composition for treating burned skin Download PDFInfo
- Publication number
- AU2004264332B2 AU2004264332B2 AU2004264332A AU2004264332A AU2004264332B2 AU 2004264332 B2 AU2004264332 B2 AU 2004264332B2 AU 2004264332 A AU2004264332 A AU 2004264332A AU 2004264332 A AU2004264332 A AU 2004264332A AU 2004264332 B2 AU2004264332 B2 AU 2004264332B2
- Authority
- AU
- Australia
- Prior art keywords
- indomethacin
- composition
- skin
- moisturizing lotion
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims description 98
- 238000000034 method Methods 0.000 title claims description 25
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 155
- 229960000905 indomethacin Drugs 0.000 claims description 77
- 239000006210 lotion Substances 0.000 claims description 38
- 230000003020 moisturizing effect Effects 0.000 claims description 37
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 21
- 235000011187 glycerol Nutrition 0.000 claims description 18
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 18
- 239000008213 purified water Substances 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 8
- 238000001959 radiotherapy Methods 0.000 claims description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 7
- 235000018330 Macadamia integrifolia Nutrition 0.000 claims description 7
- 240000000912 Macadamia tetraphylla Species 0.000 claims description 7
- 235000003800 Macadamia tetraphylla Nutrition 0.000 claims description 7
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 7
- 229940073669 ceteareth 20 Drugs 0.000 claims description 7
- 229920006037 cross link polymer Polymers 0.000 claims description 7
- 229940008099 dimethicone Drugs 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229960005323 phenoxyethanol Drugs 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 claims description 6
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 claims description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 6
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 6
- 229940043259 farnesol Drugs 0.000 claims description 6
- 229930002886 farnesol Natural products 0.000 claims description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 6
- 239000010466 nut oil Substances 0.000 claims description 6
- 229940101267 panthenol Drugs 0.000 claims description 6
- 235000020957 pantothenol Nutrition 0.000 claims description 6
- 239000011619 pantothenol Substances 0.000 claims description 6
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 6
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 claims description 6
- GVPDNFYOFKBFEN-UHFFFAOYSA-N trimethyl(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](C)(C)C GVPDNFYOFKBFEN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 claims description 5
- 229940012831 stearyl alcohol Drugs 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 description 58
- 210000003491 skin Anatomy 0.000 description 41
- 230000036407 pain Effects 0.000 description 37
- 239000000463 material Substances 0.000 description 30
- 206010042496 Sunburn Diseases 0.000 description 25
- 206010015150 Erythema Diseases 0.000 description 20
- 231100000321 erythema Toxicity 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000009467 reduction Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000006071 cream Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 229920002125 Sokalan® Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003974 emollient agent Substances 0.000 description 7
- 239000003906 humectant Substances 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 6
- 231100000075 skin burn Toxicity 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 4
- 229940043276 diisopropanolamine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010006797 Burns first degree Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- -1 steroid chemical compound Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008338 calamine lotion Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229940099261 silvadene Drugs 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- KANINNSSRWMGIP-UHFFFAOYSA-M sodium;butyl 4-hydroxybenzoate;dodecyl sulfate;hexadecan-1-ol;methyl 4-hydroxybenzoate;octadecan-1-ol;propane-1,2-diol;propyl 4-hydroxybenzoate Chemical compound [Na+].CC(O)CO.COC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1.CCCCOC(=O)C1=CC=C(O)C=C1.CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCO KANINNSSRWMGIP-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/636,404 US7714015B2 (en) | 2003-08-07 | 2003-08-07 | Method and composition for treating sunburned skin |
| US10/636,404 | 2003-08-07 | ||
| PCT/US2004/025260 WO2005016336A1 (en) | 2003-08-07 | 2004-08-05 | Method and composition for treating burned skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004264332A1 AU2004264332A1 (en) | 2005-02-24 |
| AU2004264332B2 true AU2004264332B2 (en) | 2010-09-30 |
Family
ID=34116419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004264332A Ceased AU2004264332B2 (en) | 2003-08-07 | 2004-08-05 | Method and composition for treating burned skin |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7714015B2 (enExample) |
| EP (1) | EP1656135A1 (enExample) |
| JP (1) | JP4890250B2 (enExample) |
| KR (1) | KR20060037428A (enExample) |
| AU (1) | AU2004264332B2 (enExample) |
| CA (1) | CA2524921A1 (enExample) |
| WO (1) | WO2005016336A1 (enExample) |
| ZA (1) | ZA200601054B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1863437B1 (de) * | 2005-03-24 | 2014-02-26 | Beiersdorf Ag | Verwendung von zubereitungen zum schutz hauteigener enzyme |
| WO2008115656A1 (en) * | 2007-02-22 | 2008-09-25 | Healing Skin Llc | Novel burn treatment composition |
| US20090107925A1 (en) * | 2007-10-31 | 2009-04-30 | Chevron U.S.A. Inc. | Apparatus and process for treating an aqueous solution containing biological contaminants |
| US8349764B2 (en) | 2007-10-31 | 2013-01-08 | Molycorp Minerals, Llc | Composition for treating a fluid |
| KR101985886B1 (ko) * | 2013-06-24 | 2019-06-04 | 주식회사 엘지생활건강 | 인돌 화합물 및 판테놀을 포함하는 자외선에 의한 피부손상 예방 및 개선용 조성물 |
| US12280144B2 (en) | 2019-12-19 | 2025-04-22 | Zaki Yusuf | Gel compositions for mitigation of burn injuries, kits containing the gel compositions, and associated methods |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4088754A (en) * | 1976-03-02 | 1978-05-09 | Research Corporation | Water-soluble cerium (cerous) salts in burn therapy |
| JPS57165313A (en) * | 1981-04-07 | 1982-10-12 | Nichibei Zoki Kk | Indomethacin for external use |
| US5705196A (en) * | 1991-08-08 | 1998-01-06 | Laboratorios Cusi, S.A. | Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US493362A (en) * | 1893-03-14 | Check-row corn-planter | ||
| US3629412A (en) | 1969-09-19 | 1971-12-21 | Merck & Co Inc | Topical anti-inflammatory agent |
| GB2023000B (en) | 1978-06-17 | 1982-10-13 | Kowa Co | Antinflammatory analgesic gelled ointments |
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| HU185926B (en) | 1979-09-27 | 1985-04-28 | Agostne Kahan | Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives |
| US4384000A (en) * | 1980-08-07 | 1983-05-17 | Lanier Earl W | Method for treatment of various dermatological conditions |
| US4847283A (en) | 1983-01-10 | 1989-07-11 | Harendza Harinxma Alfred J | Ointment and method for treating skin lesions due to herpes virus |
| US4732755A (en) * | 1983-01-17 | 1988-03-22 | University Of Health Sciences/The Chicago Medical School | Skin burn treatment |
| CH643138A5 (de) | 1983-08-29 | 1984-05-30 | Mepha Ag | Indomethacin enthaltende, gelartige salbe. |
| JPS60105613A (ja) * | 1983-11-15 | 1985-06-11 | Mitsubishi Chem Ind Ltd | インドメタシン外用剤 |
| DE3808039A1 (de) * | 1988-03-10 | 1989-09-21 | Bauer Johann | Kombinationspraeparat, insbesondere zur behandlung von entzuendlichen prozessen |
| US4933362A (en) | 1989-06-06 | 1990-06-12 | Jack Loomstein | Sunburn treatment composition |
| US5674912A (en) * | 1991-03-01 | 1997-10-07 | Warner-Lambert Company | Sunscreen-wound healing compositions and methods for preparing and using same |
| DE69430917T2 (de) * | 1993-05-19 | 2003-03-20 | Hisamitsu Pharmaceutical Co | 3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT |
| US5807569A (en) | 1993-05-27 | 1998-09-15 | Smithkline Beecham P.L.C. | Topical composition |
| US5558914A (en) | 1994-04-11 | 1996-09-24 | Water-Jel Technologies, Inc. | Water-based formulation for the treatment of sunburn |
| JP2723473B2 (ja) * | 1994-09-22 | 1998-03-09 | ブーク メデイテツク エイ／エス | 硫酸化糖類の用途 |
| CN1102852C (zh) * | 1995-11-13 | 2003-03-12 | 皮特迈国际有限公司 | 含一氧化二氮的止痛药、消炎药和解热药的给药介质及含有这样的介质和药物的药物组合物 |
| US6337320B1 (en) | 1996-10-11 | 2002-01-08 | Thione International, Inc. | Reparatives for ultraviolet radiation skin damage |
| US20010055599A1 (en) | 1997-05-23 | 2001-12-27 | Paul Joseph Drzewiecki | Compositions containing select liquid polyol fatty acid polyesters |
| AUPP229598A0 (en) * | 1998-03-11 | 1998-04-09 | Oldfield Family Holdings Pty Limited | Treatment of sunburn |
| US6274627B1 (en) | 1999-10-12 | 2001-08-14 | Medinox, Inc. | Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor |
| US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
| AU8466501A (en) * | 2000-07-21 | 2002-02-05 | Essentia Biosystems Inc | Multi-component biological transport systems |
| US20020143047A1 (en) | 2001-01-05 | 2002-10-03 | Galer Bradley S. | Methods for treating indomethacin responsive headaches |
-
2003
- 2003-08-07 US US10/636,404 patent/US7714015B2/en not_active Expired - Fee Related
-
2004
- 2004-08-04 US US10/911,003 patent/US7705032B2/en not_active Expired - Fee Related
- 2004-08-05 KR KR1020067002636A patent/KR20060037428A/ko not_active Abandoned
- 2004-08-05 JP JP2006522711A patent/JP4890250B2/ja not_active Expired - Fee Related
- 2004-08-05 WO PCT/US2004/025260 patent/WO2005016336A1/en not_active Ceased
- 2004-08-05 CA CA002524921A patent/CA2524921A1/en not_active Abandoned
- 2004-08-05 EP EP04780150A patent/EP1656135A1/en not_active Withdrawn
- 2004-08-05 AU AU2004264332A patent/AU2004264332B2/en not_active Ceased
-
2006
- 2006-02-06 ZA ZA200601054A patent/ZA200601054B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4088754A (en) * | 1976-03-02 | 1978-05-09 | Research Corporation | Water-soluble cerium (cerous) salts in burn therapy |
| JPS57165313A (en) * | 1981-04-07 | 1982-10-12 | Nichibei Zoki Kk | Indomethacin for external use |
| US5705196A (en) * | 1991-08-08 | 1998-01-06 | Laboratorios Cusi, S.A. | Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles |
Also Published As
| Publication number | Publication date |
|---|---|
| US7714015B2 (en) | 2010-05-11 |
| JP4890250B2 (ja) | 2012-03-07 |
| US20050032877A1 (en) | 2005-02-10 |
| ZA200601054B (en) | 2007-05-30 |
| CA2524921A1 (en) | 2005-02-24 |
| US7705032B2 (en) | 2010-04-27 |
| AU2004264332A1 (en) | 2005-02-24 |
| WO2005016336A1 (en) | 2005-02-24 |
| KR20060037428A (ko) | 2006-05-03 |
| US20050031555A1 (en) | 2005-02-10 |
| JP2007501792A (ja) | 2007-02-01 |
| EP1656135A1 (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020325925B2 (en) | Topical formulations comprising cannabidiol, method of preparing the composition and use thereof | |
| AU2015247649B2 (en) | Topical compositions for pain relief, manufacture and use | |
| US7368122B1 (en) | Skin cream | |
| AU2019203449B2 (en) | Topical diclofenac sodium compositions | |
| JP2000143507A (ja) | カプサイシン含有外用剤 | |
| JPH07504657A (ja) | 局所芳香放出組成物 | |
| JP2024016022A (ja) | 皮膚炎および炎症性皮膚状態のためのカンナビノイド投薬レジメン | |
| US20100087403A1 (en) | Topical treatment of skin infection | |
| US20220273559A1 (en) | Cbd formulations and uses thereof | |
| CA2440687A1 (en) | Dermatological preparations | |
| CN113924084A (zh) | 药物组合物 | |
| JP2015530380A (ja) | 乾癬を治療するための組成物 | |
| AU2004264332B2 (en) | Method and composition for treating burned skin | |
| JP4256125B2 (ja) | 外用組成物 | |
| US3629412A (en) | Topical anti-inflammatory agent | |
| HUT74448A (en) | Process for preparing pharmaceutical compns. contg. ibuprofen and flurbiprofen for use as anti-pruritic agents | |
| JP3187806B2 (ja) | ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤 | |
| JP2001163783A (ja) | 皮膚疾患治療用外用剤 | |
| EP1703892A2 (de) | Uv-licht stabile halbfeste transdermale systeme, die einen lichtempfindlichen wirkstoff und einen uv-absorber enthalten | |
| JPH02501303A (ja) | 全身性薬物を局所投与するための透過促進剤 | |
| JP2001226251A (ja) | 皮膚用外用組成物 | |
| TR2024002454A1 (tr) | Topical compositions comprising nimesulide and diclofenac sodium and a salicylate | |
| US20130338098A1 (en) | Topical Analgesic Compositions Containing Aliphatic Polyamines and Methods of Using Same | |
| JP2000143518A (ja) | 皮膚外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |